OPKO HEALTH, INC.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
OPK$1.710.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of September 30, 2025
CONDENSED CONSO LIDATED BALANCE SHEET
(In thousands, except share and per share data)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and current restricted cash | $415,198 | $431,936 |
| Accounts receivable, net | 94,580 | 118,017 |
| Inventory, net | 64,954 | 56,797 |
| Other current assets and prepaid expenses | 52,398 | 55,339 |
| Total current assets | 627,130 | 662,089 |
| Property, plant and equipment, net | 74,994 | 70,134 |
| Intangible assets, net | 535,378 | 616,613 |
| In-process research and development | 195,000 | 195,000 |
| Goodwill | 484,032 | 529,252 |
| Investments | 13,367 | 54,584 |
| Operating lease right-of-use assets | 45,681 | 54,003 |
| Other assets | 19,926 | 18,537 |
| Total assets | $1,995,508 | $2,200,212 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $50,827 | $47,071 |
| Accrued expenses | 95,603 | 118,357 |
| Current maturities of operating leases | 10,106 | 12,649 |
| Current portion of convertible notes | — | 170 |
| Current portion of lines of credit and notes payable | 12,785 | 14,849 |
| Total current liabilities | 169,321 | 193,096 |
| Operating lease liabilities | 36,273 | 48,849 |
| Long term portion of convertible notes | 82,699 | 173,606 |
| Senior secured notes | 246,224 | 245,576 |
| Deferred tax liabilities | 130,341 | 140,799 |
| Other long-term liabilities | 25,160 | 32,838 |
| Total long-term liabilities | 520,697 | 641,668 |
| Total liabilities | 690,018 | 834,764 |
| Equity: | ||
| Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 798,901,457 and 701,350,447 shares issued at September 30, 2025 and December 31, 2024, respectively | 7,990 | 7,015 |
| Treasury Stock - 30,199,907, and 29,799,907 shares at September 30, 2025 and December 31, 2024, respectively | (2,390) | (1,791) |
| Additional paid-in capital | 3,584,789 | 3,481,364 |
| Accumulated other comprehensive loss | (25,466) | (56,130) |
| Accumulated deficit | (2,259,433) | (2,065,010) |
| Total shareholders’ equity | 1,305,490 | 1,365,448 |
| Total liabilities and equity | $1,995,508 | $2,200,212 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
| For the three months endedSeptember 30, | For the nine months endedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: | ||||
| Revenue from services | $95,244 | $121,271 | $299,190 | $377,557 |
| Revenue from products | 37,676 | 39,143 | 113,261 | 117,675 |
| Revenue from transfer of intellectual property and other | 18,749 | 13,218 | 45,978 | 34,272 |
| Total revenues | 151,669 | 173,632 | 458,429 | 529,504 |
| Costs and expenses: | ||||
| Cost of service revenue | 80,402 | 108,847 | 247,303 | 325,798 |
| Cost of product revenue | 21,374 | 24,656 | 69,211 | 69,855 |
| Selling, general and administrative | 53,804 | 98,203 | 172,487 | 237,191 |
| Research and development | 30,078 | 28,770 | 91,261 | 74,789 |
| Amortization of intangible assets | 19,531 | 20,433 | 58,835 | 62,290 |
| Gain on sale of assets | (101,576) | (121,493) | (101,576) | (121,493) |
| Total costs and expenses | 103,613 | 159,416 | 537,521 | 648,430 |
| Operating income (loss) | 48,056 | 14,216 | (79,092) | (118,926) |
| Other income (expense), net: | ||||
| Interest income | 3,023 | 2,928 | 10,991 | 4,132 |
| Interest expense | (11,358) | (17,359) | (97,152) | (33,225) |
| Fair value changes of derivative instruments, net | (38) | (1) | (295) | (26,161) |
| Other income (expense), net | 1,748 | 48,636 | (28,915) | 128,834 |
| Other income (expense), net | (6,625) | 34,204 | (115,371) | 73,580 |
| Income (loss) before income taxes and investment losses | 41,431 | 48,420 | (194,463) | (45,346) |
| Income tax (provision) benefit | (19,797) | (23,527) | 52 | (21,898) |
| Net income (loss) before investment losses | 21,634 | 24,893 | (194,411) | (67,244) |
| Loss from investments in investees | (3) | (3) | (12) | (7) |
| Net income (loss) | $21,631 | $24,890 | $(194,423) | $(67,251) |
| Income (loss) per share: | ||||
| Income (loss) per share, basic | $0.03 | $0.04 | $(0.26) | $(0.10) |
| Income (loss) per share, diluted | $0.03 | $0.03 | $(0.26) | $(0.10) |
| Weighted average common shares outstanding, basic | 777,154,808 | 694,622,466 | 746,136,135 | 699,675,944 |
| Weighted average common shares outstanding, diluted | 779,919,259 | 998,363,636 | 746,136,135 | 699,675,944 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
| For the three months endedSeptember 30, | For the nine months endedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net income (loss) | $21,631 | $24,890 | $(194,423) | $(67,251) |
| Other comprehensive income (loss), net of tax: | ||||
| Change in foreign currency translation and other comprehensive income (loss) | (737) | 7,038 | 30,664 | (1,585) |
| Comprehensive income (loss) | $20,894 | $31,928 | $(163,759) | $(68,836) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.